AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.56 USD
-0.49 (-0.63%)
Updated Sep 16, 2025 04:00 PM ET
Pre-Market: $77.38 -0.18 (-0.23%) 9:10 AM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, AstraZeneca PLC has a market cap of $240.54B, which represents its share price of $77.56 multiplied by its outstanding shares number of 3.10B. As a large-cap company, AZN's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
AZN 77.56 -0.49(-0.63%)
Will AZN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
OLMA Stock Soars 47% in September So Far on Second PFE Deal
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
The Zacks Analyst Blog Highlights Oracle, AstraZeneca, Shopify and Blue Ridge Bankshares
Other News for AZN
Trump’s UK Visit Prompts GSK to Commit $30B in U.S. Investment
Is AZN primed for downward momentum? Stochastic Reached Oversold shows up after dropping 0.63%
Berenberg Bank Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca (AZN) Reports Positive Phase III TULIP-SC Trial Results for Saphnelo
AstraZeneca reports Saphnelo demonstrates reduction in disease activity